ClinicalTrials.gg
CompletedNCT05504226TERA 305Updated Jan 27, 2025

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

A Phase 3 interventional study of Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet and Teneligliptin Placebo Oral Tablet in Type 2 Diabetes, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Handok Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing teneligliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. teneligliptin · Diabetes Mellitus, Type 2.

Enrollment
9th of 23
214 · median 194
Started
2022
with 1 other
Phase 3
14 of 23
none open now
Registered
22nd of 23
by date
Lead sponsor
9 of 23
Handok Inc.

Among the 23 studies testing teneligliptin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 2 that started in 2022, is one of 14 in phase 3, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing teneligliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About teneligliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing teneligliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with empaglyflozin 25 mg and metformin

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Type II diabetes mellitus aged 19 years or older
  • Subjects with 7.0%≤≤10.5% at screening visit
  • Subjects with fasting plasma glucose ≤ 270mg/dL at screening visit

Exclusion criteria

Exclusion Criteria:

  • Subjects with type 1 diabetes mellitus or secondary diabetes
  • Subjects with history of diabetic ketoacidosis, diabetic coma or pre-coma, lactic acidosis, and acute or chronic acidosis within 6 months prior to the screening visit
  • Subjects who have been administered with weight-loss drug (e.g., orlistat, phentermine/topiramate, lorcaserin)
  • greater than 40 kg/m2 at the screening visit
  • Subjects with heart failure (Class III-IV of classification) or arrhythmia that requires treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Teneligliptin 20 mg

    Drug: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet

  • Placebo comparator
    Teneligliptin placebo

    Drug: Teneligliptin Placebo Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Changes from baseline HbA1c at week 24

    Time frame: Baseline (week 0) and week 24

Secondary outcomes

  1. Changes from baseline FPG at week 24

    Time frame: Baseline (week 0) and week 24

  2. Percentage of subjects achieving the HbA1c goals (HbA1c < 7.0% or < 6.5%) at week 24

    Time frame: Baseline (week 0) and week 24

  3. Changes from baseline in BMI at week 24

    Time frame: Baseline (week 0) and week 24

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Nov 2023, 13 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 17, 2022
StartActual
Oct 12, 2022
Primary completionActual
Nov 30, 2023
CompletionActual
Jun 18, 2024
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05504226
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Oct 12, 2022
Primary completion
Nov 30, 2023
Completion
Jun 18, 2024
Last update
Jan 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teneligliptin

Start the discussion